CN110831593A - 用于调节s1p1活性的化合物及其使用方法 - Google Patents

用于调节s1p1活性的化合物及其使用方法 Download PDF

Info

Publication number
CN110831593A
CN110831593A CN201880044277.0A CN201880044277A CN110831593A CN 110831593 A CN110831593 A CN 110831593A CN 201880044277 A CN201880044277 A CN 201880044277A CN 110831593 A CN110831593 A CN 110831593A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
optionally substituted
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880044277.0A
Other languages
English (en)
Chinese (zh)
Inventor
P·M·皮蒂斯
R·E·博伊德
T·A·M·多伯特
M·J·霍金斯
刘国栋
A·C·斯皮尔施内德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trevena Inc
Original Assignee
Trevena Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trevena Inc filed Critical Trevena Inc
Publication of CN110831593A publication Critical patent/CN110831593A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201880044277.0A 2017-06-14 2018-06-12 用于调节s1p1活性的化合物及其使用方法 Pending CN110831593A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762519575P 2017-06-14 2017-06-14
US62/519,575 2017-06-14
PCT/US2018/036989 WO2018231745A1 (en) 2017-06-14 2018-06-12 Compounds for modulating s1p1 activity and methods of using the same

Publications (1)

Publication Number Publication Date
CN110831593A true CN110831593A (zh) 2020-02-21

Family

ID=64660688

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880044277.0A Pending CN110831593A (zh) 2017-06-14 2018-06-12 用于调节s1p1活性的化合物及其使用方法

Country Status (9)

Country Link
US (2) US11912693B2 (enExample)
EP (1) EP3638235A4 (enExample)
JP (2) JP7252908B2 (enExample)
KR (1) KR102892521B1 (enExample)
CN (1) CN110831593A (enExample)
AU (2) AU2018282747B2 (enExample)
CA (1) CA3066423A1 (enExample)
IL (1) IL271149B2 (enExample)
WO (1) WO2018231745A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
EP3582783B1 (en) * 2017-02-17 2023-06-07 Trevena, Inc. 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
US20180282282A1 (en) 2017-03-30 2018-10-04 Genentech, Inc. Isoquinolines as inhibitors of hpk1
IL271149B2 (en) 2017-06-14 2024-05-01 Trevena Inc Compounds for modulating s1p1 activity and methods of using the same
TW202019905A (zh) 2018-07-24 2020-06-01 瑞士商赫孚孟拉羅股份公司 異喹啉化合物及其用途
TW202024053A (zh) 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
WO2020132493A1 (en) * 2018-12-21 2020-06-25 Indiana University Research And Technology Corporation Compositions and methods for suppressing and/or treating hiv-infection and/or a related clinical condition thereof
EA202191890A1 (ru) 2019-01-18 2022-02-03 Астразенека Аб Ингибиторы pcsk9 и способы их применения
US11459336B2 (en) 2019-06-14 2022-10-04 Janssen Pharmaceutica Nv Pyrazine carbamates and their use as GluN2B receptor modulators
WO2020249785A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators
MX2021015508A (es) 2019-06-14 2022-01-31 Janssen Pharmaceutica Nv Carbamatos de piridina y su uso como moduladores del receptor glun2b.
WO2020249802A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators
CR20210580A (es) 2019-06-14 2022-01-31 Janssen Pharmaceutica Nv Amidas depirazol-piridina sustituidos y su uso como moduladores del receptor glun2b
BR112021025136A2 (pt) 2019-06-14 2022-01-25 Janssen Pharmaceutica Nv Pirazolo[4,3-b]piridinas substituídas e seu uso como moduladoras do receptor de glun2b
JP7667097B2 (ja) 2019-06-14 2025-04-22 ヤンセン ファーマシューティカ エヌ．ベー． 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用
US20220315574A1 (en) * 2019-08-01 2022-10-06 Duke University Beta-Arrestin-Modulating Compounds and Methods of Using Same
BR112022003959A2 (pt) * 2019-09-05 2022-05-24 Trevena Inc Métodos para tratamento de epilepsia
CN114727977A (zh) * 2019-11-19 2022-07-08 特维娜有限公司 化合物和化合物s1p1调节剂的制备方法
US12364686B2 (en) 2020-03-27 2025-07-22 Receptos Llc Sphingosine 1 phosphate receptor modulators
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
WO2022006457A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
KR20230154194A (ko) * 2021-02-10 2023-11-07 이칸 스쿨 오브 메디슨 엣 마운트 시나이 신장 섬유증의 치료를 위한 HIPK2의 옥사디아졸릴 디하이드로피라노[2,3-b]피리딘 억제제
WO2022182839A1 (en) 2021-02-25 2022-09-01 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
JP2025509672A (ja) 2022-03-17 2025-04-11 インサイト・コーポレイション Ｊａｋ２ ｖ６１７ｆ阻害剤としての三環式尿素化合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022554A1 (en) * 2002-09-07 2004-03-18 Celltech R & D Limited Quinazolinone derivatives
TW201004944A (en) * 2008-05-02 2010-02-01 Takeda Pharmaceutical Crystalline compound
WO2014029684A1 (en) * 2012-08-20 2014-02-27 Syngenta Participations Ag Pesticidally active pyridyl- and pyrimidyl- substituted pyrazole derivatives

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4997199A (en) 1998-07-16 2000-02-07 Axys Pharmaceuticals, Inc. Process for the synthesis of benzopyran derivatives
EP1247810B1 (en) * 2001-04-04 2005-09-07 Pfizer Products Inc. Novel benzotriazoles anti-inflammatory compounds
AU2003255803A1 (en) 2002-08-23 2004-03-11 Celltech R And D Limited Quinazolinone derivatives
AU2003256003A1 (en) * 2002-09-18 2004-04-08 Pfizer Products Inc. Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors
EP2402323A3 (en) * 2004-10-13 2012-05-30 PTC Therapeutics, Inc. Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases
US7919519B2 (en) 2005-11-23 2011-04-05 Epix Pharmaceuticals Inc. S1P receptor modulating compounds and use thereof
JP5015172B2 (ja) 2005-12-23 2012-08-29 エフ．ホフマン−ラ ロシュ アーゲー アリール−イソオキサゾロ−４−イル−オキサジアゾール誘導体
AU2007236707C1 (en) 2006-04-03 2012-05-24 Astellas Pharma Inc. Hetero compound
JP2011523997A (ja) * 2008-05-30 2011-08-25 フォスター ホイーラー エナージア オサケ ユキチュア 酸素燃焼によって動力を発生させるための方法及び装置
MX2010013399A (es) * 2008-06-06 2010-12-21 Abbott Lab Nuevos compuestos de 1,2,4-oxadiazol y sus metodos de uso.
TW201000099A (en) 2008-06-20 2010-01-01 Amgen Inc S1P1 receptor agonists and use thereof
WO2010043000A1 (en) 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd S1p receptors modulators and their use thereof
TW201116212A (en) 2009-10-29 2011-05-16 Du Pont Heterobicycle-substituted azolyl benzene fungicides
EP2555772B1 (en) 2010-04-08 2017-01-11 Merck Sharp & Dohme Corp. Oxazole derivatives useful as modulators of faah
WO2011146089A1 (en) * 2010-05-21 2011-11-24 Abbott Laboratories Modulators of 5-ht receptors and methods of use thereof
EP2635573B1 (en) 2010-11-03 2014-10-01 Bristol-Myers Squibb Company Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases
CA2817071C (en) 2010-11-08 2018-04-24 Omeros Corporation Treatment of addiction and impulse-control disorders using pde7 inhibitors
BR112013028886A2 (pt) * 2011-05-10 2016-08-09 Gilead Sciences Inc compostos heterocíclicos fundidos como moduladores dde canal de sódio
CA2850394C (en) 2011-10-12 2019-05-21 University Health Network Indazole compounds as kinase inhibitors and method of treating cancer with same
EP2671881A1 (en) 2012-06-07 2013-12-11 Syngenta Participations AG. Pesticidally active pyridyl- and pyrimidyl- substituted thiazole derivatives
ES2813450T3 (es) 2013-08-19 2021-03-23 Univ California Compuestos y métodos para tratar un trastorno epiléptico
EP2853532B1 (en) 2013-09-28 2020-12-09 Instytut Farmakologii Polskiej Akademii Nauk 1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
TWI689487B (zh) * 2014-08-20 2020-04-01 美商必治妥美雅史谷比公司 經取代雙環化合物
BR112017027656B1 (pt) * 2015-06-22 2023-12-05 Arena Pharmaceuticals, Inc. Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
CA3012001A1 (en) * 2016-02-01 2017-08-10 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of nonalcoholic steatohepatitis (nash)
IL271149B2 (en) 2017-06-14 2024-05-01 Trevena Inc Compounds for modulating s1p1 activity and methods of using the same
BR112022003959A2 (pt) 2019-09-05 2022-05-24 Trevena Inc Métodos para tratamento de epilepsia
CN114727977A (zh) 2019-11-19 2022-07-08 特维娜有限公司 化合物和化合物s1p1调节剂的制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022554A1 (en) * 2002-09-07 2004-03-18 Celltech R & D Limited Quinazolinone derivatives
TW201004944A (en) * 2008-05-02 2010-02-01 Takeda Pharmaceutical Crystalline compound
WO2014029684A1 (en) * 2012-08-20 2014-02-27 Syngenta Participations Ag Pesticidally active pyridyl- and pyrimidyl- substituted pyrazole derivatives

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
D. ASHOK等: "Synthesis of Novel 2,4,6-Trisubstituted Pyrimidine Derivatives and Their in vitro Antimicrobial Activity", 《RUSSIAN JOURNAL OF GENERAL CHEMISTRY》 *
HELEN L. BIRCH等: "Novel 7-methoxy-6-oxazol-5-yl-2,3-dihydro-1H-quinazolin-4-ones as IMPDH inhibitors", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *
K. HEMALATHA等: "Binding mode of dihydroquinazolinones with lysozyme and its antifungal activity against Aspergillus species", 《JOURNAL OF PHOTOCHEMISTRY & PHOTOBIOLOGY, B: BIOLOGY》 *

Also Published As

Publication number Publication date
AU2018282747B2 (en) 2024-01-18
IL271149B1 (en) 2024-01-01
US20230234946A1 (en) 2023-07-27
JP2023078375A (ja) 2023-06-06
AU2018282747A1 (en) 2020-01-30
US11912693B2 (en) 2024-02-27
US20210188826A1 (en) 2021-06-24
KR20200020781A (ko) 2020-02-26
IL271149B2 (en) 2024-05-01
JP7252908B2 (ja) 2023-04-05
EP3638235A1 (en) 2020-04-22
WO2018231745A1 (en) 2018-12-20
AU2024202449A1 (en) 2024-05-02
BR112019026478A2 (pt) 2020-07-14
IL271149A (en) 2020-01-30
EP3638235A4 (en) 2021-06-09
CA3066423A1 (en) 2018-12-20
KR102892521B1 (ko) 2025-11-27
JP2020523390A (ja) 2020-08-06

Similar Documents

Publication Publication Date Title
KR102892521B1 (ko) S1p1 활성을 조정하기 위한 화합물 및 그를 사용하는 방법
CN114585360B (zh) 使用其治疗癫痫的方法
KR20140105445A (ko) 비아릴 에테르 술폰아미드 및 치료제로서의 그의 용도
CN108025002B (zh) 含有六元氮杂杂环的δ阿片受体调节化合物、其使用和制备方法
BR112017026535B1 (pt) Composto e composição farmacêutica
EP3582779B1 (en) 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
CN110446495B (zh) 含有7元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法
JP2024509265A (ja) 赤血球増加症を処置するための組成物および方法
BR112019026478B1 (pt) Compostos, ou sais farmaceuticamente aceitáveis dos mesmos, para modulação da atividade de s1p1; composições farmacêuticas compreendendo os mesmos e seus usos
CA2859156C (en) Treatment of type i and type ii diabetes
JP2024509267A (ja) リボソーム障害に関連する貧血を処置するための組成物および方法
HK40019187A (en) Compounds for modulating s1p1 activity and methods of using the same
HK40076272A (en) Methods of treating epilepsy using the same
HK40016700A (en) 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
HK40016699B (zh) 含有7元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法
HK40016699A (en) 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40019187

Country of ref document: HK